Related Experiment Video
Updated: Jan 15, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Genetic and transcriptomic alterations underlying aggressiveness in 5-fluorouracil-resistant HCT116 cells
Pornchai Sooksaen1, Arthid Thim-Uam2, Ratsada Praphasawat1
1Department of Pathology, School of Medicine, University of Phayao, Phayao, 56000, Thailand.
None:
Resistance to 5-fluorouracil (5-FU) remains an obstacle to effective colorectal cancer (CRC) treatment. Genetic alterations play significant roles in the development of drug-induced chemoresistance, leading to tumor recurrence and increased aggressiveness. This study sought to characterize the transcriptomic profiles of 5-FU-resistant CRC cells. HCT116 colon cancer cells were progressively exposed to increasing concentrations of 5-FU to induce resistance. Chemoresistance and aggressiveness were investigated using MTT, clonogenic, and scratch assays. Transcriptomic alterations were analyzed with next-generation sequencing (NGS). Our results revealed that 5-FU-resistant cells exhibited cross-resistance and enhanced invasive potential compared to parental HCT116 cells (HCT116-PT cells), characteristics that were associated with upregulation of matrix metalloproteinases (MMP-2 and MMP-9). Notably, we also observed significant overexpression of T cell immunoreceptor with Ig and ITIM domains (TIGIT) and cell adhesion-related genes, including neurexophilin and PC-esterase domain family member 1 (NXPE1) and neural cell adhesion molecule 1 (NCAM1). Non-coding RNAs such as microRNA-6789 (miR-6789), miR-5006, and miR-7107 were also upregulated. Pathway analysis suggested that enhanced cell survival, invasion, and apoptosis resistance in 5-FU-resistant cells may be due to the activation of several genes in the PI3K-AKT signaling pathway. In conclusion, our findings describe the transcriptomic features of chemoresistant CRC cells that are associated with aggressive tumor behavior. These insights may support the development of targeted therapies to overcome 5-FU resistance in CRC.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...